Laurie Elit

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1683278/publications.pdf

Version: 2024-02-01

933447 839539 32 361 10 18 h-index citations g-index papers 33 33 33 616 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Trends in incidence and survival of women with invasive vulvar cancer in the United States and Canada: A population-based study. Gynecologic Oncology, 2014, 134, 314-318.	1.4	70
2	The association between cervical cancer screening and mortality from cervical cancer: A population based case–control study. Gynecologic Oncology, 2014, 133, 167-171.	1.4	38
3	Sociodemographic factors associated with cervical cancer screening and follow-up of abnormal results. Canadian Family Physician, 2012, 58, e22-31.	0.4	27
4	Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options. OncoTargets and Therapy, 2013, 6, 107.	2.0	25
5	Role of cervical screening in older women. Maturitas, 2014, 79, 413-420.	2.4	21
6	Recommendations for Follow-up Care for Gynecologic Cancer Survivors. Obstetrics and Gynecology, 2015, 126, 1207-1214.	2.4	21
7	Cervical cancer in the older woman. Maturitas, 2014, 78, 160-167.	2.4	20
8	The Quality of the Operative Report for Women With Ovarian Cancer in Ontario. Journal of Obstetrics and Gynaecology Canada, 2006, 28, 892-897.	0.7	16
9	Comparing stage of diagnosis of cervical cancer at presentation in immigrant women and long-term residents of Ontario: a retrospective cohort study. CMAJ Open, 2016, 4, E424-E430.	2.4	12
10	Care Delivery Patterns, Processes, and Outcomes for Primary Ovarian Cancer Surgery: A Population-Based Review Using a National Administrative Database. Journal of Obstetrics and Gynaecology Canada, 2017, 39, 25-33.	0.7	12
11	Management of Colposcopy Patients with Biopsy-Proven Cervical Intraepithelial Neoplasia Grade 1. Journal of Lower Genital Tract Disease, 1999, 3, 191-195.	1.9	9
12	Walking a tightrope: oncologists' perspective on providing information to women with recurrent ovarian cancer (ROC) during the medical encounter. Supportive Care in Cancer, 2012, 20, 2327-2333.	2.2	9
13	Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes. Gynecologic Oncology, 2020, 157, 36-45.	1.4	9
14	Wait times from diagnosis to treatment in cancer. Journal of Gynecologic Oncology, 2015, 26, 246.	2.2	8
15	Treatment of first-void urine with Aptima Transfer Solution increases detection of high-risk HPV E6/E7 mRNA. Journal of Virological Methods, 2019, 267, 48-52.	2.1	8
16	CINtec PLUS and cobas HPV testing for triaging Canadian women referred to colposcopy with a history of low-grade squamous intraepithelial lesion: Baseline findings. Papillomavirus Research (Amsterdam, Netherlands), 2020, 10, 100206.	4.5	7
17	How to reduce the impact of cervical cancer worldwide: Gaps and priority areas identified through the essential cancer and primary care packages: An analysis of effective interventions. Cancer, 2020, 126, 4697-4705.	4.1	6
18	Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review. Critical Reviews in Oncology/Hematology, 2021, 162, 103324.	4.4	6

#	Article	IF	Citations
19	Further Insights Into Long-Term Trends in Relative Survival of Vulvar Cancer Patients: A Population-Based Study. International Journal of Gynecological Cancer, 2015, 25, 125-130.	2.5	5
20	Patient, tumor, and health system factors affecting groin node dissection rates in vulvar carcinoma: A population-based cohort study. Gynecologic Oncology, 2015, 139, 465-470.	1.4	5
21	Examining policy cohesion for cervical cancer worldwide: analysis of WHO country reports. ESMO Open, 2020, 5, e000878.	4.5	5
22	Does a groin node dissection in vulvar cancer affect groin recurrence and overall survival?: Results from a population-based cohort study. Gynecologic Oncology, 2017, 144, 318-323.	1.4	4
23	Comparison of CINtec PLUS cytology and cobas HPV test for triaging Canadian patients with LSIL cytology referred to colposcopy: A two-year prospective study. Cancer Biomarkers, 2022, 34, 347-358.	1.7	4
24	Detection of cervical precancerous lesions with Aptima HPV assays using SurePath preservative fluid specimens. Papillomavirus Research (Amsterdam, Netherlands), 2017, 3, 155-159.	4.5	3
25	Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review. Critical Reviews in Oncology/Hematology, 2021, 162, 103336.	4.4	3
26	Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline. Current Oncology, 2022, 29, 231-242.	2.2	3
27	Management of Women with Surgically Staged 1 Uterine Papillary Serous Cancer. ISRN Obstetrics & Gynecology, 2011, 2011, 1-9.	1.2	2
28	Challenges in striving to simultaneously achieve multiple resource allocation goals: the pan-Canadian Oncology Drug Review (pCODR) example. Journal of Market Access & Health Policy, 2016, 4, 31463.	1.5	1
29	Comparison of Alinity m HPV and cobas HPV assays on cervical specimens in diverse storage media. Tumour Virus Research, 2021, 12, 200224.	3.8	1
30	Who are the Providers of Gynaecologic Cancer Surgical Care in Ontario?. Journal of Obstetrics and Gynaecology Canada, 2009, 31, 721-729.	0.7	0
31	Cervical Cancer Screening in Low-Resource Settings. Journal of Obstetrics and Gynaecology Canada, 2017, 39, 1183-1184.	0.7	0
32	Incidence of venous thromboembolic events following major pelvic and abdominal surgery for cancer Journal of Clinical Oncology, 2017, 35, 478-478.	1.6	0